Relief Therapeutics Holding SA

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

Relief Therapeutics Announces Executive Changes

Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders

Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives

Relief Therapeutics has published its Annual Report

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

Relief Therapeutics Announces CEO Transition

Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East

RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders

RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100

Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update

Relief Therapeutics Announces Executive Leadership Team Change

Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders